- Home
- REFI vs ENGN Comparison
REFI vs ENGN Comparison
Compare REFI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- ENGN
- Stock Information
- Founded
- REFI 2021
- ENGN 1999
- Country
- REFI United States
- ENGN Canada
- Employees
- REFI N/A
- ENGN N/A
- Industry
- REFI Real Estate Investment Trusts
- ENGN
- Sector
- REFI Real Estate
- ENGN
- Exchange
- REFI Nasdaq
- ENGN Nasdaq
- Market Cap
- REFI 306.1M
- ENGN 317.6M
- IPO Year
- REFI 2021
- ENGN N/A
- Fundamental
- Price
- REFI $16.21
- ENGN $6.14
- Analyst Decision
- REFI Strong Buy
- ENGN Strong Buy
- Analyst Count
- REFI 3
- ENGN 9
- Target Price
- REFI $20.00
- ENGN $29.78
- AVG Volume (30 Days)
- REFI 121.4K
- ENGN 214.2K
- Earning Date
- REFI 11-07-2024
- ENGN 12-19-2024
- Dividend Yield
- REFI 11.60%
- ENGN N/A
- EPS Growth
- REFI N/A
- ENGN N/A
- EPS
- REFI 2.00
- ENGN N/A
- Revenue
- REFI $56,860,278.00
- ENGN N/A
- Revenue This Year
- REFI N/A
- ENGN N/A
- Revenue Next Year
- REFI $4.27
- ENGN N/A
- P/E Ratio
- REFI $8.11
- ENGN N/A
- Revenue Growth
- REFI 6.49
- ENGN N/A
- 52 Week Low
- REFI $14.82
- ENGN $4.42
- 52 Week High
- REFI $16.75
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- REFI 58.66
- ENGN 34.84
- Support Level
- REFI $15.69
- ENGN $5.60
- Resistance Level
- REFI $16.24
- ENGN $6.54
- Average True Range (ATR)
- REFI 0.20
- ENGN 0.70
- MACD
- REFI -0.02
- ENGN -0.11
- Stochastic Oscillator
- REFI 90.32
- ENGN 17.70
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.